Hennion & Walsh Asset Management Inc. Acquires 29,545 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Hennion & Walsh Asset Management Inc. increased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 25.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 145,599 shares of the company’s stock after purchasing an additional 29,545 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.30% of Mirum Pharmaceuticals worth $6,021,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Quest Partners LLC boosted its stake in Mirum Pharmaceuticals by 7,513.3% in the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after buying an additional 1,127 shares in the last quarter. Amalgamated Bank increased its holdings in shares of Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after buying an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after acquiring an additional 318 shares during the last quarter. ProShare Advisors LLC bought a new stake in Mirum Pharmaceuticals in the second quarter valued at approximately $213,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $215,000.

Insider Activity

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 1,998 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the completion of the transaction, the chief operating officer now owns 27,015 shares in the company, valued at $1,156,782.30. This trade represents a 6.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jolanda Howe sold 750 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the sale, the senior vice president now directly owns 2,926 shares in the company, valued at $125,291.32. This trade represents a 20.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,737 shares of company stock valued at $556,098 in the last 90 days. Company insiders own 22.87% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on MIRM shares. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Citigroup raised their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reiterated a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $57.10.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $46.60 on Thursday. The firm has a market cap of $2.24 billion, a PE ratio of -23.07 and a beta of 0.98. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $48.89. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The firm has a fifty day simple moving average of $43.07 and a two-hundred day simple moving average of $40.91.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the prior year, the company earned ($0.57) earnings per share. Mirum Pharmaceuticals’s revenue was up 89.4% on a year-over-year basis. On average, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.